Navigation Links
Extra Tests Not a Deterrent to Experimental Cancer Therapy
Date:3/4/2011

FRIDAY, March 4 (HealthDay News) -- Cancer patients are willing to tolerate multiple needle pokes, X-rays, ultrasounds, PET and CT scans to receive advanced experimental treatments in early-stage clinical trials, with some even amenable to extra tumor biopsies, according to a new study.

The finding from interviews with 61 patients with advanced cancer suggests a promising future for personalized medicine, in which doctors use specific treatments based on the genetic makeup of patients' tumors.

The study, conducted by researchers at the Mayo Clinic, Scottsdale Healthcare and the Translational Genomics Research Institute in Arizona, appears online and in the July 15 print issue of the journal Cancer.

"This is the first study of its kind where patients themselves were asked what tests and medical imaging studies they would be willing to undergo while participating in clinical studies for their cancer. Patients also were asked how invasive they perceived such tests and studies [to be]," lead author Dr. Raoul Tibes, a physician-scientist for the Mayo Clinic in Arizona, said in a Translational Genomics Research Institute news release.

To gain a better understanding about the molecular aspects of cancer, scientists need to collect tumor samples and analyze images from tests such as CT, MRI and PET scans.

"What we learned is that patients are, in general, very willing to undergo additional, extra tests to participate in clinical studies," Tibes said.

The patients said they were most willing to undergo urine, blood, ultrasound, X-ray, echocardiogram, PET and CAT scan tests. They were least willing to undergo tumor and skin biopsies and MRIs. However, most patients were willing to give one tumor biopsy sample per study, and sometimes two per study.

"This is important information, because it tells us that we can design clinical studies that ask patients to give extra tumor biopsies. But we need to carefully judge how many biopsies we request and what molecular tests we do with the tumor sample," senior study author Dr. Mitesh J. Borad, M.D., associate director of phase 1 drug development at the Mayo Clinic, said in the news release.

More information

The U.S. National Cancer Institute has more about personalized cancer care.

-- Robert Preidt

SOURCE: Translational Genomics Research Institute, news release, March 4, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Bitter melon extract attacks breast cancer cells
2. Bitter melon extract decreased breast cancer cell growth
3. Bitter Melon Extract May Slow, Stop Breast Cancer
4. Less Is More with the Innovation of Avemar(R) Fermented Wheat Germ Extract
5. Unique Equipment, Fun Workouts, Extraordinary Results
6. Green Tea Extract May Delay or Prevent Alzheimers
7. Tahitian Noni Extra Released With 16 Different Iridoids
8. Sunwin International & WILD Flavors Receive GRAS Letters of No Objection from FDA Validating Safety of Multiple Sunwin Stevia Extracts
9. Tahitian Noni Extra Sales Exceed Expectations
10. Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex
11. Human Extracellular Matrix Significantly Improves Device Biocompatibility
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Extra Tests Not a Deterrent to Experimental Cancer Therapy
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... focus on foundational and sustainable systems change designed to further positively impact the ... “The Board of Trustees has long considered it our duty to seriously consider ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... flow is Dr. Carol Francis' goals for each and every seminar, ... Dr. Carol Francis will demonstrate five different brainwave tools which help energize creativity, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of the ... 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs ... across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program ... , Trinity Health and the U.S. Soccer Foundation announced today that they have ... communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Fla. , Feb. 20, 2017 Seal ... its health IT solution for mobile device management and ... 2017 HIMSS Conference and Exhibition in Orlando, ... #4444. Mobile devices have become commonplace in ... comes a new set of concerns, including the disinfection ...
(Date:2/20/2017)... 20, 2017 According to a new market research ... powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End ... The market is projected to reach USD 52.37 Billion by 2021 from ... forecast period. Continue Reading ... ...
(Date:2/19/2017)... 2017   AC Group Inc. , a leading ... vendors in the PMS/EHR healthcare marketplace, will exhibit the ... to succeed in this ecosystem at HIMSS,17. ... obtained from over 200 ACOs, compared and analyzed an ... companies that are providing different pieces of Population Health ...
Breaking Medicine Technology: